The unique solution for multimodality follow-up in oncology, Myrian® XL-Onco, is the culmination of 8 years of development of the Myrian® platform and a partnership with the world's leading specialists.
Dedicated to oncology follow-up, it manages the sequencing of tasks essential for the management of cancer patients, with elevated efficiency and in strict compliance with RECIST international recommendations.
A complementary follow-up module based on the Cheson protocol (lymphomas) is also available.
Myrian® XL-Onco enables more effective management of cancer patients by a better evaluation of treatment response, in particular in the framework of clinical trials.
2014, February 17 - Intrasense announces that it has won simultaneously nine tenders with some of the most prestigious reference sites across the country.
NYSE Euronext now lists Intrasense on NYSE Alternext in Paris